Wells Fargo
CTXR icon

Wells Fargo’s Citius Pharmaceuticals CTXR Stock Holding History

Wells Fargo’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$605 Buy
+1,000
New +$677 ﹤0.01% 6502
2026
Q1 		– Sell
-40
Closed -$31 – 7234
2025
Q4 		$31 Hold
40
– – ﹤0.01% 6632
2025
Q3 		$50 Buy
+40
New +$56 ﹤0.01% 6485
2024
Q3 		– Sell
-160
Closed -$2.33K – 6942
2024
Q2 		$2.33K Sell
160
-1,874
-92% -$33.6K ﹤0.01% 5991
2024
Q1 		$45.6K Buy
2,034
+379
+23% +$6.92K ﹤0.01% 5296
2023
Q4 		$31.3K Buy
1,655
+298
+22% +$5.65K ﹤0.01% 5455
2023
Q3 		$23.2K Sell
1,357
-702
-34% -$16.7K ﹤0.01% 5538
2023
Q2 		$61.8K Buy
2,059
+1,862
+945% +$61.3K ﹤0.01% 5322
2023
Q1 		$5.77K Hold
197
– – ﹤0.01% 6016
2022
Q4 		$3.88K Buy
197
+1
+0.5% +$27 ﹤0.01% 5833
2022
Q3 		$6K Hold
196
– – ﹤0.01% 5847
2022
Q2 		$5K Sell
196
-993
-84% -$27.2K ﹤0.01% 5997
2022
Q1 		$53K Sell
1,189
-1,497
-56% -$59.1K ﹤0.01% 5624
2021
Q4 		$103K Sell
2,686
-23,258
-90% -$1.06M ﹤0.01% 5615
2021
Q3 		$1.32M Buy
25,944
+25,762
+14,155% +$1.29M ﹤0.01% 4013
2021
Q2 		$15K Buy
182
+73
+67% +$4.39K ﹤0.01% 5999
2021
Q1 		$5K Buy
109
+18
+20% +$717 ﹤0.01% 6491
2020
Q4 		$2K Buy
91
+1
+1% +$26 ﹤0.01% 6263
2020
Q3 		$2K Buy
90
+5
+6% +$141 ﹤0.01% 6128
2020
Q2 		$2K Sell
85
-658
-89% -$14.4K ﹤0.01% 6089
2020
Q1 		$11K Buy
743
+663
+829% +$14K ﹤0.01% 5728
2019
Q4 		$2K Hold
80
– – ﹤0.01% 6163
2019
Q3 		$2K Hold
80
– – ﹤0.01% 6188
2019
Q2 		$2K Hold
80
– – ﹤0.01% 6162
2019
Q1 		$3K Buy
+80
New +$2.35K ﹤0.01% 5801

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM

Wells Fargo's CTXR Position: Q2 2026 in Review

Wells Fargo opened a new position in Citius Pharmaceuticals (CTXR) in Q2 2026: 1,000 shares worth $605. The stake represents ﹤0.01% of the portfolio and ranks #6502 among its holdings. This is a return to the name: Wells Fargo previously reported a position in CTXR as recently as Q4 2025.

Wells Fargo first reported a position in CTXR in Q1 2019 and has held it in 25 quarters since. The position peaked at $1.32M in Q3 2021. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

  • Wells Fargo held 1,000 shares of Citius Pharmaceuticals worth $605 as of Q2 2026.
  • Citius Pharmaceuticals was a new Wells Fargo position in Q2 2026.
  • Citius Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6502 holding.
  • Wells Fargo first reported a position in Citius Pharmaceuticals in Q1 2019 and has held it in 25 quarters since.
  • Wells Fargo's Citius Pharmaceuticals position peaked at $1.32M in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.